Terri L. Meinking
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Terri L. Meinking has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Deborah H. Eyerdam
Global Health Associates of Miami, Inc. (GHAM), Miami, Florida
3 shared publicationsMaureen Vicaria
Global Health Associates of Miami (GHAM), Miami, Florida
3 shared publicationsSusan Reyna
Women United in Justice, Education and Reform (MUJER), Miami, Florida
3 shared publicationsGerman Suarez
Global Health Associates of Miami, Inc. (GHAM), Miami, Florida
2 shared publicationsMaria Elena Villar
Global Health Associates of Miami, Inc. (GHAM), Miami, Florida
2 shared publicationsDebbie H. Eyerdam
Global Health Associates of Miami (GHAM), Miami, Florida
1 shared publication
Latest Publications
- 26 December 2012
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (1) , 106-112
Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation
Background Ivermectin is a broad‐spectrum parasiticide in widespread systemic use, including as an off‐label treatment for head lice infestation. The potential of the topical use of ivermectin as a treatment for head lice infestation was suggested by an in vitro report of a novel lotion formulation.Objectives This study investigated the relative effectiveness of three ivermectin lotion concentrations (0.15, 0.25, and 0.5%) compared with vehicle placebo in eliminating head lice infestation.Methods In this randomized, blinded study, 78 head lice‐infested subjects, aged 2–62 years, received a single, 10‐minute application of product on day 1. Evaluations were completed at two and six hours post‐application, and on days 2, 8 (±1), and 15 (+2). Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports. Efficacy was assessed according to scalp and hair examinations.Results Compared with placebo, all ivermectin concentrations resulted in the statistically significant (P ≤ 0.003) eradication of head lice through to day 15, with the highest level of eradication (73.7%) in subjects who received the 0.5% concentration. The severity of pruritus decreased from baseline in all treatment groups, including the placebo group, from six hours post‐treatment to day 15, with the greatest reduction in the 0.5% concentration group. No ocular irritation was observed. All three ivermectin treatment strengths and vehicle were well tolerated.Conclusions A single application of a 0.5% concentration of this ivermectin lotion formulation shows promise as a safe and effective treatment for head lice infestation and the associated signs of pruritus.
- 26 December 2012
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (1) , 106-112
Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation
Background Ivermectin is a broad‐spectrum parasiticide in widespread systemic use, including as an off‐label treatment for head lice infestation. The potential of the topical use of ivermectin as a treatment for head lice infestation was suggested by an in vitro report of a novel lotion formulation.Objectives This study investigated the relative effectiveness of three ivermectin lotion concentrations (0.15, 0.25, and 0.5%) compared with vehicle placebo in eliminating head lice infestation.Methods In this randomized, blinded study, 78 head lice‐infested subjects, aged 2–62 years, received a single, 10‐minute application of product on day 1. Evaluations were completed at two and six hours post‐application, and on days 2, 8 (±1), and 15 (+2). Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports. Efficacy was assessed according to scalp and hair examinations.Results Compared with placebo, all ivermectin concentrations resulted in the statistically significant (P ≤ 0.003) eradication of head lice through to day 15, with the highest level of eradication (73.7%) in subjects who received the 0.5% concentration. The severity of pruritus decreased from baseline in all treatment groups, including the placebo group, from six hours post‐treatment to day 15, with the greatest reduction in the 0.5% concentration group. No ocular irritation was observed. All three ivermectin treatment strengths and vehicle were well tolerated.Conclusions A single application of a 0.5% concentration of this ivermectin lotion formulation shows promise as a safe and effective treatment for head lice infestation and the associated signs of pruritus.
- 1 January 2010
- Published by Wiley in Pediatric Dermatology
- Vol. 27 (1) , 19-24
The Clinical Trials Supporting Benzyl Alcohol Lotion 5% (UlesfiaTM): A Safe and Effective Topical Treatment for Head Lice (Pediculosis Humanus Capitis)
Benzyl alcohol lotion 5% (BAL 5%) is a non-neurotoxic topical head lice treatment that is safe and effective in children as young as 6 months of age. The safety and efficacy of this pediculicide has been studied in 695 (confirm number) subjects in all phases of clinical development. Scanning electron micrographs (SEM) demonstrated that the active agent appears to stun the breathing spiracles open, enabling the vehicle to penetrate the respiratory mechanism (spiracles), therefore asphyxiating the lice. Initial phase II trials compared this novel product to RID using identical volumes of treatment (4 oz/application) and yielding, almost, identical efficacy. This outcome pointed to the significant importance of completely saturating the hair with the product in order to achieve maximum treatment success. A second phase II trial, which allowed the use of sufficient product to saturate the hair, resulted in 100% efficacy after both 10 and 30 minute treatments. A third phase II trial verified an effective dose. Phase III trials compared BAL 5% to vehicle placebo for two 10-minute applications. It proved to be safe and effective (p < 0.001) for treatment of head lice and is the first FDA-approved non-neurotoxic lice treatment, now available in the United States as Ulesfia lotion.
- 1 January 2010
- Published by Wiley in Pediatric Dermatology
- Vol. 27 (1) , 19-24
The Clinical Trials Supporting Benzyl Alcohol Lotion 5% (UlesfiaTM): A Safe and Effective Topical Treatment for Head Lice (Pediculosis Humanus Capitis)
Benzyl alcohol lotion 5% (BAL 5%) is a non-neurotoxic topical head lice treatment that is safe and effective in children as young as 6 months of age. The safety and efficacy of this pediculicide has been studied in 695 (confirm number) subjects in all phases of clinical development. Scanning electron micrographs (SEM) demonstrated that the active agent appears to stun the breathing spiracles open, enabling the vehicle to penetrate the respiratory mechanism (spiracles), therefore asphyxiating the lice. Initial phase II trials compared this novel product to RID using identical volumes of treatment (4 oz/application) and yielding, almost, identical efficacy. This outcome pointed to the significant importance of completely saturating the hair with the product in order to achieve maximum treatment success. A second phase II trial, which allowed the use of sufficient product to saturate the hair, resulted in 100% efficacy after both 10 and 30 minute treatments. A third phase II trial verified an effective dose. Phase III trials compared BAL 5% to vehicle placebo for two 10-minute applications. It proved to be safe and effective (p < 0.001) for treatment of head lice and is the first FDA-approved non-neurotoxic lice treatment, now available in the United States as Ulesfia lotion.
- 1 July 2007
- Published by Wiley in Pediatric Dermatology
- Vol. 24 (4) , 405-411
A Randomized, Investigator‐Blinded, Time‐Ranging Study of the Comparative Efficacy of 0.5% Malathion Gel Versus Ovide®Lotion (0.5% Malathion) or Nix® Crème Rinse (1% Permethrin) Used as Labeled, for the Treatment of Head Lice
Abstract: One hundred seventy‐two subjects with head lice participated in a five‐way, investigator‐blinded, parallel‐group, active‐controlled study comparing 0.5% malathion gel (30, 60, and 90 minutes applications), Ovide® Lotion (0.5% malathion), and Nix® Crème Rinse (1% permethrin). All subjects were treated on day 1. Participants were reevaluated at day 8 ± 1 and those with live lice were retreated with the same product, for the same duration as day 1. Cure, defined as the absence of live lice, was evaluated 14 ± 2 days after the last treatment and 161 subjects completed the study according to the protocol. Compared to Nix, treatment success rates were statistically superior for all malathion gel and Ovide® groups. Retreatment rate for Nix was 70%, which was statistically more than the malathion groups. The highest treatment success rates were observed for the 30‐minute malathion gel (98% intent‐to‐treat and 100% per‐protocol [PP]) and the 8 to 12 hour Ovide® application (97% intent‐to‐treat and 100% PP). In conclusion, the 30‐minute malathion gel, which contains the same ingredients and concentrations as Ovide®, provides comparable efficacy, offers increased safety and is more cosmetically acceptable than Ovide®.
- 1 July 2007
- Published by Wiley in Pediatric Dermatology
- Vol. 24 (4) , 405-411
A Randomized, Investigator‐Blinded, Time‐Ranging Study of the Comparative Efficacy of 0.5% Malathion Gel Versus Ovide®Lotion (0.5% Malathion) or Nix® Crème Rinse (1% Permethrin) Used as Labeled, for the Treatment of Head Lice
Abstract: One hundred seventy‐two subjects with head lice participated in a five‐way, investigator‐blinded, parallel‐group, active‐controlled study comparing 0.5% malathion gel (30, 60, and 90 minutes applications), Ovide® Lotion (0.5% malathion), and Nix® Crème Rinse (1% permethrin). All subjects were treated on day 1. Participants were reevaluated at day 8 ± 1 and those with live lice were retreated with the same product, for the same duration as day 1. Cure, defined as the absence of live lice, was evaluated 14 ± 2 days after the last treatment and 161 subjects completed the study according to the protocol. Compared to Nix, treatment success rates were statistically superior for all malathion gel and Ovide® groups. Retreatment rate for Nix was 70%, which was statistically more than the malathion groups. The highest treatment success rates were observed for the 30‐minute malathion gel (98% intent‐to‐treat and 100% per‐protocol [PP]) and the 8 to 12 hour Ovide® application (97% intent‐to‐treat and 100% PP). In conclusion, the 30‐minute malathion gel, which contains the same ingredients and concentrations as Ovide®, provides comparable efficacy, offers increased safety and is more cosmetically acceptable than Ovide®.
- 27 February 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (3) , 327-328
Thrips mistaken for headlice or Ekban Syndrome
- 27 February 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (3) , 327-328
Thrips mistaken for headlice or Ekban Syndrome
- 30 November 2004
- Published by Wiley in Pediatric Dermatology
- Vol. 21 (6) , 670-674
Efficacy of a Reduced Application Time of Ovide Lotion (0.5% Malathion) Compared to Nix Creme Rinse (1% Permethrin) for the Treatment of Head Lice
Abstract: Our objective was to conduct a randomized, investigator‐blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis. Either Ovide or Nix was applied according to the label instructions. However, Ovide application time was reduced to 20 minutes. At day 8, subjects with live lice were re‐treated with the same product and procedure as on day 1. Ovicidal and pediculicidal efficacy were evaluated at days 8 and 15. A subject free of lice and viable eggs at day 15 was considered to be a treatment success. Percent efficacy was calculated using the number of subjects free of lice and viable eggs per total number of subjects treated. We found that a 20‐minute application of Ovide was significantly more pediculicidal and ovicidal (98%) compared to Nix (55%) at day 15 (p < 0.0001). The percentage of Ovide subjects who required treatment at day 8 was half that of the Nix group. The reinfestation rate was 0% with Ovide and 33% with Nix. In conclusion, a 20‐minute treatment with Ovide, instead of the approved 8‐ to 12‐hour application, cured 40 of 41 subjects (98%), demonstrating superior efficacy to Nix. The poor efficacy of Nix confirms the resistance of head lice to permethrin in south Florida.
- 30 November 2004
- Published by Wiley in Pediatric Dermatology
- Vol. 21 (6) , 670-674
Efficacy of a Reduced Application Time of Ovide Lotion (0.5% Malathion) Compared to Nix Creme Rinse (1% Permethrin) for the Treatment of Head Lice
Abstract: Our objective was to conduct a randomized, investigator‐blinded evaluation of the pediculicidal and ovicidal activity of a reduced application time (20 minutes) of Ovide (0.5% malathion) compared to Nix (1% permethrin) in a south Florida population infested with Pediculus humanus capitis. Either Ovide or Nix was applied according to the label instructions. However, Ovide application time was reduced to 20 minutes. At day 8, subjects with live lice were re‐treated with the same product and procedure as on day 1. Ovicidal and pediculicidal efficacy were evaluated at days 8 and 15. A subject free of lice and viable eggs at day 15 was considered to be a treatment success. Percent efficacy was calculated using the number of subjects free of lice and viable eggs per total number of subjects treated. We found that a 20‐minute application of Ovide was significantly more pediculicidal and ovicidal (98%) compared to Nix (55%) at day 15 (p < 0.0001). The percentage of Ovide subjects who required treatment at day 8 was half that of the Nix group. The reinfestation rate was 0% with Ovide and 33% with Nix. In conclusion, a 20‐minute treatment with Ovide, instead of the approved 8‐ to 12‐hour application, cured 40 of 41 subjects (98%), demonstrating superior efficacy to Nix. The poor efficacy of Nix confirms the resistance of head lice to permethrin in south Florida.